CDMO makes four new executive appointments.
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and contract development and manufacturing organization (CDMO), has made four recent executive appointments. Joining the company are Tony Fraij, COO; Shaguna Seth, chief of staff and global PMO leader; Katie Edgar, SVP of corporate strategy and alliance management; and Sarah Wakefield, SVP, corporate communications.
“I am thrilled to welcome these four exceptional experts to KBI. Each of them brings unique insight, has an impressive track record, and is fully aligned with our KBI vision as we navigate the evolving landscape of our industry and seize opportunities for success,” said J.D. Mowery, KBI Biopharma CEO. “They will all play vital roles in shaping our future at KBI, enabling us to be the best and most trusted partner to our global biopharmaceutical customers.”
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.